Two new β3 integrin mutations in Indian patients with Glanzmann thrombasthenia: Localization of mutations affecting cysteine residues in integrin β3

Thrombosis and Haemostasis

Volumn 88, Issue 3, 2002, Pages 503-509

  Nair, Sona ^a   Li, Jihong ^a   Mitchell, W Beau ^a   Mohanty, Dipika ^a   Coller, Barry S ^a   French, Deborah L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Glanzmann thrombasthenia; Platelets; IIb 3

Indexed keywords

ABCIXIMAB; ADENOSINE DIPHOSPHATE; ALPHA2B BETA3 ANTIBODY; ALPHA5 ANTIBODY; ANTIBODY; BETA3 INTEGRIN; CYSTEINE; DIMER; FIBRINOGEN; IRON; LM 142; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 10E5; MONOCLONAL ANTIBODY 6D1; MONOCLONAL ANTIBODY LM 609; RISTOCETIN; THROMBOCYTE ALPHA2B BETA3 RECEPTOR; THROMBOCYTE RECEPTOR; UNCLASSIFIED DRUG; DISULFIDE; GLYCOPROTEIN IIB;

ADULT; ANAMNESIS; ARTICLE; BANGLADESH; BIOGENESIS; BLEEDING; BLOOD TRANSFUSION; CASE REPORT; CELL LEVEL; CELL LYSATE; CELL MIGRATION; CONTROLLED STUDY; DISEASE SEVERITY; DISULFIDE BOND; ECCHYMOSIS; EPISTAXIS; FEMALE; FLOW CYTOMETRY; GENE; GENE MUTATION; GINGIVA BLEEDING; GLANZMANN DISEASE; HOMOZYGOSITY; HUMAN; IMMUNOBLOTTING; INDIA; IRON DEFICIENCY; ISOTOPE LABELING; MALE; MENORRHAGIA; MISSENSE MUTATION; MOLECULAR WEIGHT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; THROMBOCYTE; THROMBOCYTE AGGREGATION; CHEMISTRY; FAMILY HEALTH; FRAMESHIFT MUTATION; GENETICS; HOMOZYGOTE; MUTATION; NUCLEOTIDE SEQUENCE; PROTEIN CONFORMATION;

ADULT; BLOOD PLATELETS; CHILD, PRESCHOOL; DISULFIDES; DNA MUTATIONAL ANALYSIS; FAMILY HEALTH; FEMALE; FRAMESHIFT MUTATION; HOMOZYGOTE; HUMANS; INDIA; INTEGRIN BETA3; MALE; MUTATION; MUTATION, MISSENSE; PLATELET MEMBRANE GLYCOPROTEIN IIB; PROTEIN CONFORMATION; THROMBASTHENIA;

EID: 0036712297     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH2002880503     Document Type: Article

References (50)

1. Glanzmann's thrombasthenia: The spectrum of clinical disease
2. The molecular genetics of Glanzmann's thrombasthenia
3. A Glanzmann's thrombasthenia cluster among Iraqi Jews in Israel
4. Glanzmann's thrombasthenia. A review and report of 42 cases from South India
5. The molecular genetic basis of Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations in Israel
6. Glanzmann thrombasthenia caused by an 11.2-kb deletion in the glycoprotein IIIa (β3) is a second mutation in Iraqi Jews that stemmed from a distinct founder
7. Identification of a region in glycoprotein IIIa involved in subunit association with glycoprotein IIb: Further lessons from Iraqi-Jewish Glanzmann thrombasthenia
8. The molecular genetic basis of Glanzmann's thrombasthenia in a Gypsy population in France: Identification of a new mutation on the αIIb gene
9. Prevention of Glanzmann thrombasthenia in Southern India by haplotype analysis and mutation identification
10. Platelet function disorders in northern India
11. Immunologic and biochemical characterization of homozygous and heterozygous Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations in Israel: Comparison of techniques for carrier detection
12. Studies with a murine monoclonal antibody that abolishes ristocetin-induced binding of von Willebrand factor to platelets: Additional evidence in support of GPIb as a platelet receptor for von Willebrand factor
13. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds glycoproteins IIb and/or IIIa
14. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex
15. Humanizing the constant region of the 7E3 murine monoclonal Fab antibody fragment reduces the immunogenicity of the variable region in humans
16. Biosynthetic and functional properties of an arg-gly-asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor
17. Type I Glanzmann thrombasthenia patients from the Iraqi-Jewish and Arab populations in Israel can be differentiated by platelet glycoprotein IIIa immunoblot analysis
18. Partial inhibition of platelet aggregation and fibrinogen binding by a murine monoclonal antibody to GPIIIa: Requirement for antibody bivalency
19. Glycoprotein IIb Leu214Pro mutation produces Glanzmann thrombasthenia with both quantitative and qualitative abnormalities in GPIIb/IIIa
20. Platelet-collagen adhesion: Inhibition by a monoclonal antibody that binds glycoprotein IIb
21. Divalent cation regulation of the surface orientation of platelet membrane glycoprotein IIb. Correlation with fibrinogen binding function and definition of a novel variant of Glanzmann's thrombasthenia
22. Crystal structure of the extracellular segment of integrin alpha Vbeta3
23. Cysteine-rich module structure reveals fulcrum for integrin rearrangement upon activation
24. Homozygous Cys542→Arg substitution in GPIIIa in a Swiss patient with type I Glanzmann's thrombasthenia
25. Megakaryocyte-targeted synthesis of the integrin beta3-subunit results in the phenotypic correction of Glanzmann thrombasthenia
26. A Cys374Tyr homozygous mutation of platelet glycoprotein IIIa (β3) in a Chinese patient with Glanzmann's thrombasthenia
27. Two different beta3 cysteine substitutions alter alphaIIbbeta3 maturation and result in Glanzmann thrombasthenia
28. Three novel integrin beta3 subunit missense mutations (H280P, C560F, and G579S) in thrombasthenia, including one (H280P) prevalent in Japanese patients
29. A point mutation in the cysteine-rich domain of glycoprotein (GP) IIIa results in the expression of a GPIIb-IIIa (alphaIIbbeta3) integrin locked in a high-affinity state and a Glanzmann thrombasthenia-like phenotype
30. Probing conformation changes in the I-like domain and the cysteine-rich repeat of human beta3 integrins following disulfide bond disruption by cysteine mutations
31. A point mutation leads to an unpaired cysteine residue and a molecular weight polymorphism of a functional platelet β3 integrin subunit
32. A1: Evidence for heterogeneity in the humoral response
33. Truncation of the cytoplasmic domain of β3 in a variant form of Glanzmann thrombasthenia abrogates signaling through the integrin αIIbβ3 complex
34. 655 in glycoprotein IIIa does not affect the function of platelet glycoprotein IIb-IIIa
35. Protein disulfide isomerase mediates platelet aggregation and secretion
36. Protein disulfide isomerase mediates integrin-dependent adhesion
37. The platelet integrin alphaII-bbeta3 has an endogenous thiol isomerase activity
38. A redox site involved in integrin activation
39. Protein disulfide isomerase and sulfhydryl-dependent pathways in platelet activation
40. Platelet aggregation caused by dithiothreitol
41. Regulation of platelet aggregation by post-fibrinogen binding events. Insights provided by dithiothreitol-treated platelets
42. The integrin αIIb-β3, platelet glycoprotein IIb-IIIa, can form a functionally active heterodimer complex without the cysteine-rich repeats of the β3 subunit
43. Disruption of the long-range GPIIIa Cys5-Cys435 disulfide bond results in the production of a constitutively active GPIIb-IIIa integrin complex
44. Further examination of the role of GPIIIa long-range Cys5-Cys435 disulfide bond in conformational changes of GPIIb-IIIa: Substitution of cysteine 5 with alanine results in the production of a constitutively active GPIIb-IIIa integrin complex
45. A mutation in the extra-cellular cysteine-rich repeat region of the β3 subunit activates integrins αIIbβ3 and αvβ3
46. Probing chemical and conformational differences in the resting and active conformers of platelet integrin alphaIIbbeta3
47. Nonsense-mediated mRNA decay in health and disease
48. ER-associated and proteasome-mediated protein degradation: How two topologically restricted events came together
49. The genomic organization of platelet glycoprotein IIIa
50. Isolation and characterization of a TATA-less promoter for the human β3 integrin gene